Myokardia Inc (NASDAQ: MYOK) shares jumped 74.1 percent to $29.86. MyoKardia posted a Q2 loss of $0.41 per share on sales of $5.63 million. The company also reported 'positive' topline results in Phase 2 PIONEER-HCM study.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to NxStage Medical (NXTM):